论文部分内容阅读
Objective To investigate clinical observation of solifenacin combined with Ningmitai Capsule in treating female patients with overactive bladder.Methods 106 female patients with overactive bladder were choosen and then randomly divided into control and observation groups.Patients in control group took solifenacin only while the observation group patients on this basis accepted Ningmitai Capsule.Urodynamic studies,the efficacy of OABSS,PPBC,QOL score and voiding diary were evaluated after treatment.Results After treatment,bladder compliance(BC),the initial the urinate capacity(the FDV),maximum bladder pressure capacity(MCBC)and residual volume(RV)of the observation group were(40.41 ± 11.48)ml/cm H2O、(186.96±73.19)ml、(316.39±104.62)ml and(6.44±3.57)ml respectively,which were significantly improved(P <0.05)compared with BC(54.91 ±16.95)ml/cm H2O,FDV(154.71± 48.23)ml,MCBC(268.45 ± 92.78)ml,RV(31.75± 7.38)ml in the control group.OABSS,PPBC and QOL score of the observation group were respectively(4.12 ± 1.46)point,(1.74 ± 0.79)point,(1.43 ± 1.02)point,which were improved significantly(P <0.05)compared with OABSS(6.49 ± 1.92)point,PPBC(2.86 ± 0.87)point and QOL(2.91 ± 0.90)point of the control group after treatment.24 hours urgency of the observation group was(1.5 ± 0.7),which decreased significantly(P <0.05)than that of the control group(2.3 ± 1.7).Conclusion solifenacin combined with Ningmitai Capsule can effectively improve the urgency and other symptoms and improve quality of life for female patients with overactive bladder.